This automated platform employs a ferrofluid-coupled antibody to magnetically capture CTCs derived from carcinomas through targeting the epithelial cell adhesion molecule (EpCAM) which is not expressed by blood cells. This evidence concerns the gene EPCAM and carcinoma.